These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21130255)

  • 21. Re: Hara et al.: Decline of the red cell blood count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor 1 and erythropoesis. (Urology 2010;75:1441-1445).
    Colloca G; Venturino A; Vitucci P
    Urology; 2010 Oct; 76(4):1020. PubMed ID: 20932425
    [No Abstract]   [Full Text] [Related]  

  • 22. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Quality of life of patients with prostatic cancer under hormonal therapy].
    Aliaev IuG; Aslamazov EG; Demidko IuL
    Urologiia; 2010; (1):46, 48-51. PubMed ID: 20891045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
    Collier A; Ghosh S; McGlynn B; Hollins G
    Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
    Lage MJ; Barber BL; Markus RA
    Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should we follow-up serum testosterone in patients with advanced prostate cancer?
    Perachino M
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1031-5. PubMed ID: 20645692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal therapy and radiation for prostate cancer: is it safe?
    Nanda A; D'Amico AV
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):979-81. PubMed ID: 20645684
    [No Abstract]   [Full Text] [Related]  

  • 29. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis.
    Guan J; Khambhati J; Jones LW; Morgans A; Allaf M; Penson DF; Moslehi J
    Circulation; 2015 Nov; 132(18):e218-20. PubMed ID: 26527696
    [No Abstract]   [Full Text] [Related]  

  • 31. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 32. [Androgen deprivation therapy and morbid obesity: do they share cardiovascular risk through metabolic syndrome?].
    Cleffi S; Neto AS; Reis LO; Maia P; Fonseca F; Wroclawski ML; Neves M; Pompeo AC; Del Giglio A; Faria EF; Tobias-Machado M
    Actas Urol Esp; 2011 May; 35(5):259-65. PubMed ID: 21459486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
    Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U
    BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
    Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
    J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen deprivation therapy for precancerous lesions of the prostate.
    Hull D; Bostwick DG
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer.
    Curtis KK; Pruthi RK; Fonseca R; Gornet MK
    Urology; 2007 Oct; 70(4):811.e5-8. PubMed ID: 17991572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The benefits of early androgen blockade.
    Maroni PD; Crawford ED
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.